Lage H - Search Results

1

Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.

Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, Lage H. Materna V, et al. Among authors: lage h. Oncol Rep. 2007 Mar;17(3):505-16. Oncol Rep. 2007. PMID: 17273726

2

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.

Materna V, Pleger J, Hoffmann U, Lage H. Materna V, et al. Among authors: lage h. Gynecol Oncol. 2004 Jul;94(1):152-60. doi: 10.1016/j.ygyno.2004.03.035. Gynecol Oncol. 2004. PMID: 15262134

3

Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.

Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczyński M, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: lage h. Cancer Lett. 2006 Apr 28;235(2):272-80. doi: 10.1016/j.canlet.2005.04.035. Epub 2005 Jun 20. Cancer Lett. 2006. PMID: 15970376

4

Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.

Surowiak P, Materna V, Drag-Zalesinska M, Wojnar A, Kaplenko I, Spaczyński M, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: lage h. Int J Gynecol Pathol. 2006 Apr;25(2):131-9. doi: 10.1097/01.pgp.0000183050.30212.2f. Int J Gynecol Pathol. 2006. PMID: 16633061

5

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: lage h. Clin Cancer Res. 2006 Dec 1;12(23):7149-58. doi: 10.1158/1078-0432.CCR-06-0564. Clin Cancer Res. 2006. PMID: 17145840

6

CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients.

Surowiak P, Materna V, Maciejczyk A, Kaplenko I, Spaczynski M, Dietel M, Lage H, Zabel M. Surowiak P, et al. Among authors: lage h. Anticancer Res. 2006 Nov-Dec;26(6C):4943-8. Anticancer Res. 2006. PMID: 17214367 Free article.

7

Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.

Materna V, Surowiak P, Kaplenko I, Spaczyński M, Duan Z, Zabel M, Dietel M, Lage H. Materna V, et al. Among authors: lage h. Virchows Arch. 2007 Feb;450(2):187-94. doi: 10.1007/s00428-006-0346-7. Virchows Arch. 2007. PMID: 17216190

8

Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.

Surowiak P, Materna V, Maciejczyk A, Pudełko M, Markwitz E, Spaczyński M, Dietel M, Zabel M, Lage H. Surowiak P, et al. Among authors: lage h. Virchows Arch. 2007 Mar;450(3):279-85. doi: 10.1007/s00428-006-0362-7. Epub 2007 Jan 19. Virchows Arch. 2007. PMID: 17235562

9

Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor.

Surowiak P, Materna V, Maciejczyk A, Pudelko M, Suchocki S, Kedzia W, Nowak-Markwitz E, Dumanska M, Spaczynski M, Zabel M, Dietel M, Lage H. Surowiak P, et al. Among authors: lage h. Histol Histopathol. 2008 May;23(5):531-8. doi: 10.14670/HH-23.531. Histol Histopathol. 2008. PMID: 18283637

10

Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.

Materna V, Liedert B, Thomale J, Lage H. Materna V, et al. Among authors: lage h. Int J Cancer. 2005 Jun 20;115(3):393-402. doi: 10.1002/ijc.20899. Int J Cancer. 2005. PMID: 15688364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters